8-K: Ekso Bionics Reports Third Quarter 2024 Financial Results, Achieves Key Reimbursement Milestone

Ekso Bionics announced its third quarter 2024 financial results, including revenue of $4.1 million and the achievement of initial CMS reimbursement for its Ekso Indego Personal device.

Summary

• Ekso Bionics reported a revenue of $4.1 million for the third quarter of 2024, compared to $4.6 million in the same period of 2023.
• The company sold 33 EksoHealth devices in the third quarter of 2024.
• Gross profit for the quarter was $2.2 million, with a gross margin of 53.5%, slightly up from 53.3% in the same period last year.
• The company's net loss for the quarter narrowed to $2.1 million, or $0.10 per share, compared to a net loss of $3.4 million, or $0.24 per share, in the third quarter of 2023.
• For the nine months ended September 30, 2024, revenue was $12.8 million, compared to $13.4 million in the same period of 2023.
• The company sold 99 EksoHealth devices in the first nine months of 2024.
• The net loss for the first nine months of 2024 was $7.9 million, or $0.42 per share, compared to a net loss of $12.0 million, or $0.88 per share, in the same period of 2023.
• Ekso Bionics completed an underwritten offering in September 2024, resulting in net proceeds of approximately $5.0 million.
• Cash on hand was $8.3 million as of September 30, 2024, compared to $8.6 million at the end of 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the achievement of CMS reimbursement and the narrowing of net losses, despite a slight decrease in revenue. The successful capital raise also contributes to the positive outlook.

Positives

• The company achieved initial CMS reimbursement for Ekso Indego Personal, a significant milestone for the company and spinal cord injury patients.
• Gross margin increased to 53.5% in the third quarter of 2024, driven by cost savings in the supply chain and reduced service costs.
• Sales and marketing expenses decreased by 14% in the third quarter of 2024 due to lower headcount and discretionary spending.
• Research and development expenses decreased by 33% in the third quarter of 2024 due to reduced use of product development consultants.
• The net loss narrowed significantly for both the third quarter and the first nine months of 2024 compared to the same periods in 2023.
• Net cash used in operating activities decreased to $8.4 million in the first nine months of 2024, compared to $10.5 million in the same period of 2023.

Negatives

• Revenue decreased to $4.1 million in the third quarter of 2024, compared to $4.6 million in the same period of 2023.
• Revenue for the first nine months of 2024 was $12.8 million, compared to $13.4 million in the same period of 2023.
• General and administrative expenses increased in the third quarter of 2024 due to higher consulting costs.

Risks

• The company's future success depends on obtaining adequate financing to fund operations and develop technology.
• The company's ability to obtain future reimbursements from CMS in a timely manner and at expected levels is uncertain.
• The company faces risks related to obtaining insurance coverage beyond CMS.
• The company's success depends on achieving broad market acceptance of its products.
• The company faces competition and potential disruptions in its supply chain.
• The company's ability to implement its business plans and strategies is subject to various risks and uncertainties.

Future Outlook

The company remains focused on expanding access to its EksoHealth devices and expects procurement cycles with Integrated Delivery Networks to normalize in the near-term. They are also actively working to increase CMS claim submissions.

Management Comments

• Scott Davis, the Company's Chief Executive Officer, stated that the receipt of initial CMS reimbursement for Ekso Indego Personal was a major milestone.
• Management is actively collaborating with neuro-rehabilitation facilities, physicians, and DMEs to lay the groundwork for future sales.

Industry Context

Ekso Bionics operates in the growing exoskeleton technology market, focusing on both medical and industrial applications. The achievement of CMS reimbursement is a significant step for the company, as it opens up a larger market for its medical devices. The company is competing with other exoskeleton manufacturers and medical device companies.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the gross margin of 53.5% is a key metric to compare against other medical device companies.
• The company's focus on CMS reimbursement is a common strategy in the medical device industry, particularly for products targeting rehabilitation and mobility.
• The decrease in operating expenses, particularly in sales and marketing and R&D, is a positive sign, but needs to be compared to industry averages to assess efficiency.
• The net loss per share of $0.10 for the quarter and $0.42 for the nine months needs to be compared to similar companies in the medical device sector to determine if it is in line with industry standards.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the capital raise.
• Employees may be affected by changes in headcount and discretionary spending.
• Customers, particularly those with spinal cord injuries, will benefit from the CMS reimbursement for Ekso Indego Personal.
• Suppliers may be impacted by changes in the company's supply chain.
• Creditors will be impacted by the company's financial performance and debt levels.

Next Steps

• The company will continue to expand access to its EksoHealth devices.
• The company will focus on increasing CMS claim submissions.
• The company will work to normalize procurement cycles with Integrated Delivery Networks.
• Management will host a conference call to discuss the financial results and recent business developments.

Key Dates

Keywords

exoskeleton, Ekso Bionics, medical devices, rehabilitation, CMS reimbursement, financial results, wearable robots, spinal cord injury, EksoHealth, gross margin